Details of Drug

Details of Drug

 Drug General Information (ID: D1008)
  Drug Name
Meropenem
  Drug Type Small molecule
  Drug Synonymous
MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
    Click to Show/Hide
  Disease Class 1A00-1C4Z: Bacterial infection
  Therapeutic Class Antibiotics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C17H25N3O5S
  InChI 1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
  InChIKey DMJNNHOOLUXYBV-PQTSNVLCSA-N
  Canonical SMILES CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O
  External Link
Pubchem ID 441130
CAS Number 96036-03-2
CHEBI ID 43968
TTD ID D0O5FY
INTEDE ID DR2491
VARIDT ID DR01200

Drug-Drug Interaction Network
  Sunburst Graph
AM001  Affected gastrointestinal absorption
AM002  Affected cellular transport
AM003  Affected organization distribution
AM005  Affected excretion pathways
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM002  Altered intestinal flora
BM010  Transporter inhibition
BM014  Interference of cell/tissue uptake
BM028  Competitive inhibition of renal tubular secretion
BM069  Increased risk of lowers seizure threshold
BM087  Antagonize the effect of antiepileptic agents
BM100  Antagonize the effect of vaccine/toxoid
BM107  Attenuated pharmacological effects (Unspecific)
  Relation Graph
 Full list of drugs interacting with Meropenem
      Affected gastrointestinal absorption
   Altered intestinal flora Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1095
 
Mycophenolic acid
 
C17H20O6
 
446541 
Moderate    Inter Info   
[52], [53]
D1094
 
Mycophenolate mofetil
 
C23H31NO7
 
5281078 
Moderate    Inter Info   
[52], [53]
      Affected cellular transport
   Transporter inhibition Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0044
 
Alpelisib
 
C19H22F3N5O2S
 
56649450 
Moderate    Inter Info   
[21], [35], [36]
D0569
 
Encorafenib
 
C22H27ClFN7O4S
 
50922675 
Moderate    Inter Info   
[21], [39]
D1143
 
Nitisinone
 
C14H10F3NO5
 
115355 
Moderate    Inter Info   
[61]
      Affected organization distribution
   Interference of cell/tissue uptake Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1817
 
Indium In-111 oxyquinoline
 
C27H18InN3O3
 
16685037 
Moderate    Inter Info   
[51]
      Affected excretion pathways
   Competitive inhibition of renal tubular secretion Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0576
 
Entecavir
 
C12H15N5O3
 
135398508 
Moderate    Inter Info   
[30]
D1341
 
Probenecid
 
C13H19NO4S
 
4911 
Moderate    Inter Info   
[59], [60]
D1241
 
Pemetrexed
 
C20H21N5O6
 
135410875 
Moderate    Inter Info   
[62]
      Pharmacodynamic additive effects
   Increased risk of lowers seizure threshold Drug Num:  10
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0220
 
Bupropion
 
C13H18ClNO
 
444 
Major    Inter Info   
[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15]
D0833
 
Iohexol
 
C19H26I3N3O9
 
3730 
Major    Inter Info   
[16], [17], [18], [19], [20]
D0834
 
Iopamidol
 
C17H22I3N3O8
 
65492 
Major    Inter Info   
[16], [17], [18], [19], [20]
D1616
 
Tramadol
 
C16H25NO2
 
33741 
Major    Inter Info   
[25], [14], [13], [26]
D0678
 
Fluphenazine
 
C22H26F3N3OS
 
3372 
Moderate    Inter Info   
[31], [21]
D0932
 
Lindane
 
C6H6Cl6
 
727 
Moderate    Inter Info   
[32], [33], [34]
D0054
 
Amifampridine
 
C5H7N3
 
5918 
Moderate    Inter Info   
[37], [38]
D0722
 
Ginkgo biloba
 
NA
 
NA
Moderate    Inter Info   
[43], [44], [45], [46], [47], [48], [49], [50]
D1308
 
Polyethylene glycol (3350 with electrolytes)
 
C2H6O2
 
174 
Moderate    Inter Info   
[57], [58], [21]
D1488
 
Sodium sulfate
 
Na2O4S
 
24436 
Moderate    Inter Info   
[57], [21], [58]
      Pharmacodynamic antagonistic effects
   Antagonize the effect of antiepileptic agents Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1677
 
Valproic acid
 
C8H16O2
 
3121 
Major    Inter Info   
[27], [28], [29]
   Antagonize the effect of vaccine/toxoid Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1914
 
Typhoid vaccine (live)
 
NA
 
NA
Major    Inter Info   
[21], [22], [23]
D1693
 
Vibrio cholerae CVD 103-HgR strain live antigen (live)
 
NA
 
NA
Major    Inter Info   
[24]
   Attenuated pharmacological effects (Unspecific) Drug Num:  4
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0606
 
Estradiol
 
C18H24O2
 
5757 
Moderate    Inter Info   
[40], [41], [42]
D0619
 
Ethinylestradiol
 
C20H24O2
 
5991 
Moderate    Inter Info   
[40], [41], [42]
D1011
 
Mestranol
 
C21H26O2
 
6291 
Moderate    Inter Info   
[40], [41], [42]
D1287
 
Picosulfuric acid
 
C18H15NO8S2
 
5243 
Moderate    Inter Info   
[54], [55], [56]
References
1 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
2 Sheehan DV, Welch JB, Fishman SM "A case of bupropion-induced seizure." J Nerv Ment Dis 174 (1986): 496-8. [PMID: 3090199]
3 Canadian Pharmacists Association.
4 Product Information. Wellbutrin (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
5 Gittelman DK, Kirby MG "A seizure following bupropion overdose." J Clin Psychiatry 54 (1993): 162. [PMID: 8486598]
6 Product Information. Wellbutrin SR (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
7 James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
8 Masco HL, Kiev A, Holloman LC, Batey SR, Johnston JA, Lineberry CG "Safety and efficacy of bupropion and nortriptyline in outpatients with depression." Curr Ther Res Clin Exp 55 (1994): 851-63.
9 Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
10 Product Information. Zyban (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
11 Storrow AB "Bupropion overdose and seizure." Am J Emerg Med 12 (1994): 183-4. [PMID: 8161393]
12 Johnston JA, Lineberry CG, Ascher JA, et al. "A 102-center prospective study of seizure in association with bupropion." J Clin Psychiatry 52 (1991): 450-6. [PMID: 1744061]
13 Rosenstein DL, Nelson JC, Jacobs SC "Seizures associated with antidepressants: a review." J Clin Psychiatry 54 (1993): 289-99. [PMID: 8253696]
14 Pisani F, Spina E, Oteri G "Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice." Epilepsia 40(Suppl 10) (1999): S48-56. [PMID: 10609604]
15 Product Information. Aplenzin (buPROPion). sanofi-aventis , Bridgewater, NJ.
16 Product Information. Isovue-M-200 (iopamidol). Bracco Diagnostics Inc, Princeton, NJ.
17 Product Information. Amipaque (metrizamide) Nycomed Inc, Princeton, NJ.
18 Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35. [PMID: 810000]
19 Product Information. Omnipaque 180 (iohexol). Amersham Health, Princeton, NJ.
20 Product Information. Osmovist 240 (iotrolan). Berlex Canada Inc, Lachine, QC.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 UK government "Typhoid.".
23 American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association (1994).
24 Product Information. Vaxchora (cholera vaccine, live). PaxVax, Miami, FL.
25 Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
26 Gardiner JS, Blough D, Drinkard CR, et al. "Tramadol and seizures: a surveillance study in a managed care population." Pharmacotherapy 20 (2000): 1423-31. [PMID: 11130214]
27 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."
28 Molnar GP, Stephens KJ, George LV, Stewart JT "A critical interaction between ertapenem and valproic acid." J Clin Psychopharmacol 35 (2015): 348-50.[PMID: 25871574]
29 Tobin JK, Golightly LK, Kick SD, Jones MA "Valproic acid-carbapenem interaction: report of six cases and a review of the literature." Drug Metabol Drug Interact 24(2-4) (2009): 153-82.[PMID: 20408498]
30 Product Information. Baraclude (entecavir). Bristol-Myers Squibb, Princeton, NJ.
31 Cerner Multum, Inc. "Australian Product Information.".
32 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
33 Cox R, Krupnick J, Bush N, Houpt A "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc 41 (2000): 690-2. [PMID: 10974795]
34 Product Information. Kwell (lindane). Reed and Carnrick, Jersey City, NJ.
35 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
37 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
38 Product Information. Firdapse (amifampridine). Catalyst Pharmaceuticals, Inc., Coral Gables, FL.
39 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
40 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
41 Barnett ML "Inhibition of oral contraceptive effectiveness by concurrent antibiotic administration." J Periodontol 56 (1985): 18-20. [PMID: 3882930]
42 King VJ "OC failure rates and oral antibiotics." J Fam Pract 45 (1997): 104-5. [PMID: 9267366]
43 Kajiyama Y, Fujii K, Takeuchi H, Manabe Y "Ginkgo seed poisoning." Pediatrics 109 (2002): 325-7. [PMID: 11826216]
44 Granger AS "Ginkgo biloba precipitating epileptic seizures." Age Ageing 30 (2001): 523-5. [PMID: 11742783]
45 Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11. [PMID: 9818800]
46 Spinella M "Herbal medicines and epilepsy: the potential for benefit and adverse effects." Epilepsy Behav 2 (2001): 524-32. [PMID: 12609386]
47 Gregory PJ "Seizure associated with Ginkgo biloba?." Ann Intern Med 134 (2001): 344. [PMID: 11182853]
48 Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE "Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder." Epilepsia 47 (2006): 323-9. [PMID: 16499756]
49 Miwa H, Iijima M, Tanaka S, Mizuno Y "Generalized convulsions after consuming a large amount of Gingko nuts." Epilepsia 42 (2001): 280-1. [PMID: 11240603]
50 Kupiec T, Raj V "Fatal seizures due to potential herb-drug interactions with Ginkgo biloba." J Anal Toxicol 29 (2005): 755-8. [PMID: 16419414]
51 Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111). GE Healthcare, Princeton, NJ.
52 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
53 Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate). Ferring Pharmaceuticals Inc, Tarrytown, NY.
55 MHRA. Medicines and Healthcare Regulatory Agency (general site Reference).
56 Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate). Ferring Pharmaceuticals Inc, Tarrytown, NY.
57 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
58 Salik JM, Kurtin P "Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome." Am J Gastroenterol 80 (1985): 177-9. [PMID: 2983533]
59 Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ "The pharmacokinetics of meropenem in volunteers." J Antimicrob Chemother 24(suppl a (1989): 311-20. [PMID: 2808215]
60 Product Information. Merrem (meropenem). Zeneca Pharmaceuticals, Wilmington, DE.
61 Product Information. Orfadin (nitisinone). Orphan Pharmaceuticals USA, Inc, Nashville, TN.
62 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.